Introduction
Fibrinogen is a 340 kilodalton dimeric glycoprotein that is composed of two identical halves, each of which consists of three non-identical polypeptides termed A , B and chains. The halves of the molecule are associated at the N-terminal regions by a series of disulfide bonds 2, 3 . Fibrinogen plays an important role in three major biological processes: 1) conversion of soluble fibrinogen into fibrin after activation of blood coagulation; 2) fibrinogen-derived fibrin serves as a template for the activation and localization of the fibrinolytic system that induces the dissolution of the fibrin clot, and 3) fibrinogen interacts with platelets, white cells and endothelial cells to mediate several biological processes, including hemostasis, inflammation, wound healing and angiogenesis. Fibrin formation is initiated by the enzymatic activity of thrombin that cleaves fibrinopeptides A and B from the N-terminal region of the A and B chains, resulting in exposure of polymerization sites "A" and "B", respectively. Fibrin polymerization is initiated by binding of exposed site " A " with a complementary site, "a", localized in the C-terminus of the chain of an adjacent fibrin molecule. This association organizes the initial fibrin polymer into a halfstaggered overlap of two-stranded protofibrils [2] [3] [4] . Removal of fibrinopeptide B and exposure of the "B"
site promotes the lateral aggregation of the protofibrils that produces fibrin fibers that aggregate with each other to yield fibrin bundles, which branch, resulting in a fibrin gel 2, 3, 4, 5 . Finally, the fibrin polymer is cross-linked by factor XIIIa that forms new peptide bonds between specific lysine and glutamine residues, resulting in the formation of -dimers and polymers 6 which increases the strength of the clot and makes it more resistant to fibrinolysis [7] [8] [9] [10] . Fibrinogen is synthesized and assembled inside the hepatocyte and secreted into the circulation, where its plasma half-life ranges from 3 to 4 days 1, 11 .
Genetic disorders involving fibrinogen have been classified as quantitative alterations, (mainly afibrinogenemia and hypofibrinogenemia), alterations of function (dysfibrinogenemia) and combined defects (hypodysfibrinogenemia) [12] [13] [14] [15] . Approximately 300 families with dysfibrinogenemia have been described and more than 50 molecular defects have been identified 12, 16, 17 . The clinical expression of dysfibrinogenemias varies, roughly 60 percent are clinically silent, and the other 40 percent are almost equally associated with bleeding and thrombosis, and in few instances the abnormal fibrinogen is associated with both manifestations. Rarely, the abnormal fibrinogens have been associated with spontaneous abortions 12, 13 , delayed wound healing 13 or amyloidosis of the kidney 13 . In some hypodysfibrinogenemia mutants, the structurally abnormal fibrinogen with altered functional activity is combined with a low fibrinogen concentration, arbitrarily defined as below 1.5 mg/ml, as measured by
For personal use only. on September 14, 2017 . by guest www.bloodjournal.org From immunological methods. About 15 families with hypodysfibrinogenemia have been fairly well characterized and in the majority of these, the functional defect is reflected in an abnormal polymerization phase, while a delay in fibrinopeptide release is the exception. Rarely, an abnormal interaction with platelets and endothelial cells has been described. Clinically, the individuals with hypodysfibrinogenemia may present with bleeding, thrombosis or spontaneous abortions 12, 13 .
Previously 1 , fibrinogen isolation, chromatographic studies, SDS-PAGE, fibrinopeptide release, fibrin polymerization, cross-linking, metabolic studies and general coagulation tests, including euglobulin lysis time and presence of fibrinogen-fibrin degradation products in serum were examined in the fibrinogen Philadelphia kindred. Briefly, we showed that fibrinogen concentration, measured by immunological methods, ranged between 0.45 and 0.78 mg/ml. The thrombin time of plasma or purified fibrinogen was very prolonged in affected members and improved after addition of calcium. The euglobulin lysis time and amounts of fibrinogen-fibrin degradation products in serum were normal. Sizes of the three fibrinogen chains, estimated by SDS-PAGE, were also normal. Functionally, although fibrinopeptide release was normal, the formed fibrin monomers showed a marked decrease in final turbidity. However, the formed fibrin monomers demonstrated a delay in polymerization, especially when monomers were incubated in high ionic strength medium. Metabolic studies done on the proband and her son, using autologous and homologous fibrinogen showed a marked decrease in half-life in plasma of 46 and 38 hours of the autologous protein compared with 72 and 74 hours for the normal counterpart. These metabolic studies indicate that the hypercatabolism is due to an intrinsic molecular defect of the patients' fibrinogen since the normal protein had a normal metabolism. In this report, we examine ability of the fibrinogen to polymerize and characterize clot structure made from the proband's purified fibrinogen, expand analysis of the kindred, define the molecular abnormality of fibrinogen Philadelphia, and describe a model to explain the altered polymerization.
Methods

Study Population
This study was approved by the Thomas Jefferson University Institutional Review Board and all patients were given informed consent.
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DNA Isolation
Genomic DNA was isolated from peripheral blood using Puregene DNA Isolation kit (Gentra Systems, Minneapolis, MN) and from buccal brushings using BuccalAmp DNA Extraction Kit (Epicentre, Madison, WI) as per the manufacturers' instructions.
PCR Amplification
Coding regions and exon/intron borders of the three fibrinogen genes (A, B, G) were amplified with genespecific primer pairs (A. Fellowes, personal communication). PCR reactions were performed using 200 ng genomic DNA, 200 ng of forward and reverse primers, 0.2 mM dNTP, 1.5 mM MgCl 2, and Jumpstart Taq Polymerase (Sigma-Aldrich Corp., St. Louis, MO) in a 100 µl reaction. PCR conditions were 5 minutes at 95°C followed by 30 cycles of 94°C for 30 seconds, 52-62°C for 30 seconds and 72°C for 30-60 seconds followed by a final extension of 72°C for 5 minutes. Annealing temperature and extension times were varied. In family members where genomic DNA was limited, PCR products were used as template in a second PCR amplification to generate sufficient material for DNA sequence analysis. PCR products were purified using Montage PCR tubes (Millipore Corp., Billerica, MA) and quantified by comparison to size markers on agarose gels.
Plasmid cloning of PCR products PCR products encompassing exon 9 of the fibrinogen G gene were cloned into the TA cloning vector, pCR2.1, and the plasmid transformed into OneShot Top10 competent bacteria as per the manufacturer's instructions (Invitrogen, Carlsbad, CA). Resulting colonies were screened for the presence of inserts using PCR colony screening with M13 forward and reverse primers. Clones containing inserts were further screened in two PCR reactions, containing one exon 9 fibrinogen primer and either the M13 forward or reverse primer, since cloning was not unidirectional. Positive clones were grown and plasmid DNA was isolated using Qiagen miniprep kit (Qiagen, Valencia, CA). Resulting plasmid DNA was subjected to DNA sequence analysis. Ten clones from each individual were sequenced in order to confirm the presence of the two alleles (exon 9 T or C).
DNA Sequence Analysis
Amplified fragments (~ 100 ng) were sequenced using BigDye3.1 dye terminators (Applied Biosystems, Foster City, CA) as per manufacturer's instructions and analyzed on a ABI 3100 Capillary electrophoresis For personal use only. on September 14, 2017. by guest www.bloodjournal.org From system using 50 cm capillaries with POP6 polymer and Data Collection and Sequencing Analysis v1.1 software packages (ABI). A fragment containing exons 9 and 10 was amplified using FGG7501for (5 -ctg gca atg cac ttc gta at-3 ) and FGG8376rev (5 -ctc tct gtt cag ata aag tcc-3 ) and sequence analysis was performed with nested primers FGG7530for (5 -ttc ata gac ttg cag agg ta-3 ) and FGG7737rev (5 -ggt ggt gtt gct gtc ctt ct-3 ).
Genotyping of fibrinogen G promoter polymorphism (-597A G)
The 5'-flanking region of the fibrinogen G gene was amplified with FGG-827for (5 -agg gcc aaa cag aaa tga tg-3 ) and FGG-101rev (5 -tct ttc ccg ttc ctt ttt cc-3 ) primers, and the resulting 726 bp product was digested with 10 units of Bse RI (New England Biolabs, Beverly, MA) for 4 hours followed by electrophoresis on a 3 % (w/v) SeaKem agarose (Cambrex, East Rutherford, NJ) gel. Digestion of PCR products with an A at -597 results in 337, 226, 86 and 77 bp products, while those with a G results in 233, 226, 10, 86 and 77 bp products. Alternatively, PCR products were subjected to DNA sequence analysis using a nested primer FGG-678for (5 -cct ggc tct ttt ctc tgt gg-3 ).
Contig Assembly and Analysis
Sequence chromatogram files were imported into Sequencher software (GeneCodes, Inc, Ann Arbor, MI) and assembled into contigs using fibrinogen reference sequences (Genbank accession NT006258).
Heterozygous nucleotide positions were identified by divergence from the reference sequence. 
Scanning and Transmission Electron Microscopy of Fibrin Clots
Mean fiber diameter and size distribution (mean ± SD; n = 500) were measured from transmission electron microscope samples prepared as described previously 18 . Clots were formed as described for the turbidity measurements, but were dispersed with a glass Pasteur pipet as they began to gel after the addition of thrombin (1.0-2.5 minutes). Sample volumes of 5-20 µL were pipetted onto freshly glowdischarged, 300 mesh carbon-coated Formvar grids, negatively contrasted with filtered 2% uranyl acetate, and allowed to air-dry. Samples were viewed at 80 kV in a JEOL-100B transmission electron microscope (JEOL, Inc, Peabody, MA) and fiber measurements were made from photographic enlargements of transmission electron microscope negatives. 
Protein Structure Prediction
Swiss-Pdb Viewer 21 was used to generate a model of the C-terminal portion of the gamma chain of fibrinogen Philadelphia containing the S378P mutation using the pdb file 1FIC derived from the crystal structure of the 30 kDa C-terminal fragment 22 . The program determines the "best fit" structure, putative hydrogen bonds and steric hindrances. Images were imported into Pov RAY v3.6 23 and converted to graphics format for publication.
Results
Molecular Defect Determined
To determine the molecular defect of fibrinogen Philadelphia, DNA sequence analysis of the three fibrinogen genes, A, B and G, in the proband was performed. The DNA sequence of the A and B genes matched the reference sequence (accession number NT_006258). Sequence analysis of the G gene showed two nucleotide changes compared to the reference sequence: a T C change in exon 9 that is predicted to result in a serine to proline substitution (TCC CCC) at amino acid 378 in the C-terminus of the chain (S378P) and an A G change in the promoter 597 nucleotides upstream of the transcription start site (A-597). All members of the kindred tested were homozygous for the fibrinogen G promoter -597 A G change. This nucleotide change is reported in the single nucleotide polymorphism database dbSNP (http://www.ncbi.nlm.nih.gov/SNP/; #rs1800792), and has an allele frequency of 42 %, similar to the 50 % frequency seen when ten Caucasian controls were screened using PCR-RFLP analysis.
Exon 9 of the fibrinogen G gene was subsequently analyzed in the son (111-2) and grandson (IV-1), both of whom have hypodysfibrinogenemia as well as in the unaffected granddaughter (IV-2) (see Figure 1) .
In order to confirm the presence of two alleles at codon 378 in exon 9 in members of the family in which genomic DNA was limiting, PCR products were cloned into a shuttle vector, and resulting vectors subjected to DNA sequence analysis with a reverse primer. Sequence analysis of PCR products generated from the proband showed heterozygosity at this position and two representative clones showed each of the alleles (data not shown). The son and grandson, but not the unaffected granddaughter, were heterozygous for the T C change resulting in S378P, as indicated in the pedigree in Figure l . This nucleotide change was not present in ten control individuals screened by DNA sequence analysis.
Molecular Modeling
The effect of the fibrinogen Philadelphia mutation on the structure of the gamma chain was investigated by using DeepView SPD Viewer and entering the serine to proline change in the 1FIC of the 30 kDa C- Table 1 ). On the other hand, at 0.05 M ionic strength, the turbidity curves for fibrinogen Philadelphia were nearly normal but the lag period was shorter ( Table 1) . Fibrinogen Philadelphia clots form alpha and gamma chain cross-links in the presence of factor XIIIa. The rate of crosslinking was similar to that of control clots (data not shown).
Electron Microscopy Reveals Abnormal Clot Structure
Transmission electron microscopy of negatively-stained clots was performed to examine the details of clot structure under these same ionic conditions. Samples generally were taken every 2 minutes after the addition of thrombin, and fiber diameters and fiber densities were measured to correlate these observations with results seen in turbidity experiments. In most cases, the clots from fibrinogen Philadelphia appeared as a mesh of fibers of uniform size (Fig. 4A) . Fibers displayed the band pattern (Fig. 4B) , indicating that assembly proceeded in the normal manner with halfstaggered molecular packing (13) . Diameters of fibers from fibrinogen Philadelphia clots made at 0.2 M buffer with Ca ++ for 10 minutes were 80% of those of control clots (62 ± 20 vs. 75 ± 27, p < 0.0001, Table 1 ). In contrast, under the same conditions the mean fiber diameter and size distribution after 2 minutes of polymerization were the same for both fibrinogens despite the fact that fibrin Philadelphia clots had reached absorbance values nearly twice those of normal fibrin at the same time point (0.19 vs. 0.10, p < 0.0001, Table 1 ). However, the fiber density in transmission electron microscopy images of fibrinogen Philadelphia clots was considerably greater, accounting for the greater turbidity. Samples polymerized in 0.40 M buffer with Ca ++ were poorly formed, with long, thin fibers with little bundling and irregularly spaced branch points (data not shown). Fiber diameters were greatly reduced at high ionic strength (see Table 1 ), especially for fibrinogen Philadelphia clots, as predicted from the turbidity curves.
A greater proportion of thin fibers and protofibrils were seen in the micrographs of fibrinogen Philadelphia clots prepared in 0.2 M NaCl, 0.02 M citrate buffer.
Scanning electron microscopy of whole clots was carried out to examine clot structure and fiber diameter after thrombin-induced polymerization was complete (Figure 4C and D) . Measurements of mean fiber diameter in scanning electron microscopy images prepared under the same buffer conditions described above yielded differences comparable to those seen in transmission electron microscopy samples ( Table   1) . In other words, clots from fibrinogen Philadelphia had fiber diameters consistently lower than those of control clots. In addition, fiber ends were consistently seen in fibrin Philadelphia clots but not in controls (Fig. 4C, arrowheads) .
Additional Family Members Examined
Thrombin-clottable and immunodetectable fibrinogen levels were determined in three additional family members more than twenty years after the initial description of fibrinogen Philadelphia (1). Two children of the affected son (III-2) of the proband (II-2), and the proband's daughter were examined for immunologic levels of fibrinogen. Abnormally low levels were present in one grandson (IV-1), while the daughter (III-1) and granddaughter (IV-2) had normal levels (Figure 1) . These additional findings further support autosomal dominant transmission of this genetic disorder.
Discussion
We have examined clot formation and structure and determined the molecular defect of Fibrinogen Philadelphia, one of the first reported hypodysfibrinogenemias, an autosomal dominant condition functionally characterized by abnormal fibrin polymerization and ~ 30 % of normal plasma fibrinogen levels. Thrombin-catalyzed polymerization of fibrinogen Philadelphia under a variety of conditions was characterized by a shorter lag period and lower maximum turbidity. On the other hand, although the initial characterization of mutant fibrin monomer had determined that clots formed from fibrin monomer at low ionic strength had lower final turbidity 1 , this was not the case when fibrinogen was clotted with thrombin under low salt conditions ( Table 1 ). The reason for this difference is that polymerization is different with the sequential release of fibrinopeptides induced by thrombin than with fibrin monomer already missing both fibrinopeptides 5 . With the polymerization of fibrinogen Philadelphia, the differences from control were most striking at high ionic strength or with low calcium at normal ionic strength. The results presented here reinforce the conclusion that lateral aggregation is sensitive to both ionic strength and calcium, suggesting that these interactions are ionic and involve the low affinity calcium-binding sites. Consistent with these findings, transmission and scanning electron microscopy revealed clots composed of considerably thinner fibers. Although other dysfibrinogenemias are characterized by clots made up of thin fibers, the shortened lag period appears to be unique to fibrinogen
Philadelphia. Approximately 91% of branchpoints in Fibrinogen Philadelphia clots were tri-functional, similar to the 92% seen in control clots 25, 26 .
The molecular defect S378P was present in three affected family members, and was absent in one unaffected member, indicating that the non-conservative S378P change in exon 9 of the fibrinogen G gene is the cause of hypodysfibrinogenemia in this kindred. The three genes, A, B and G, that encode the three fibrinogen chains (A , B and ) are localized to a cluster on chromosome 4 (4q23-q32), are composed of 6, 8 and 10 exons, respectively 27, 28 and are under coordinate control. Point mutations in the G gene are the most common cause of congenital dysfibrinogenemias which are functionally expressed as defects in fibrin polymerization, although alterations in cross-linking also have been described 29 .
Our current knowledge of how fibrinogen is processed and interacts as well as the location of other mutations aid in understanding how the S378P mutation is associated with the biochemical, functional and clinical phenotypes seen in the fibrinogen Philadelphia kindred. After the proteolytic cleavage of
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From fibrinopeptide A by thrombin, the new N-terminal region exposes a polymerization site, named site "A", that binds to a constitutively active complementary site termed "a" of adjacent fibrin molecules, localized in the C-terminal globular domain of the chain formed by several amino acids localized between G329 and R375 [2] [3] [4] 30, 31 . This association results in the formation of a double-stranded protofibril in which the fibrin monomers are arranged in a half-staggered overlap 4 . Closely associated with the site "a" is the calcium-binding site pocket, where two aspartate residues, D318 and D320, play a fundamental role in calcium binding, and mutations of this segment may alter the proper folding of the molecule, resulting in defective fibrin polymerization 29 . The C-terminal region of the chain also participates in the association DD, where two molecules of fibrin associate through their C-terminal region which is involved in the longitudinal growth of the protofibril 32 and mutations of this area of the chain can cause delays in fibrin polymerization 33 . The S378P mutation does not affect the DD interface or Factor XIII-induced crosslinking, as it is not close to these regions (see Figure 2) . After the protofibrils reach a certain length they start to associate laterally to form fibrin fibers which branch to generate the fibrin gel. The molecular interactions involved in lateral aggregation are rather complex [34] [35] [36] and not fully elucidated; our discussion will be limited to the role of the gamma chain in this process. It appears that the chain may promote the lateral growth of fibrin fibers by direct interaction of the chains of different protofibrils via -chain segments 350-360 and 360-380 24 . Since the S378P substitution in fibrinogen Philadelphia is in this region and we have observed striking effects of this mutation on the thickness of fibers, our results are consistent with this model. When the crystal structure of the C-terminal fragment of the gamma chain is used to generate a molecular model, the S378 is located in a loop connecting two beta sheets 22 . One might speculate that substitution of serine with proline in a turn might not have a major effect on the tertiary structure of this region of the molecule. Whereas most dysfibrinogenemias that result in clots with low turbidity (thin fibers) also have an increased lag period, fibrinogen Philadelphia does not, suggesting that this abnormality is mainly due to a defect in lateral aggregation. Fibrinogen Paris I is structurally characterized by the insertion of 15 amino acids after Gamma Q350, and functionally manifests as a polymerization defect with normal cross-linking of the wild-type gamma chains and no cross-linking of the gamma Paris I chains 37 . Analysis of the clot by EM also reveals abnormal clumps with irregular fibers and frequent terminations 38 .
Consistent with such conclusions is the low turbidity at high salt concentration (see Table 1 ), which has a characteristic effect on lateral aggregation. Interestingly, the lag period for fibrinogen Philadelphia is actually decreased under most conditions, indicating that this mutation also enhances the For personal use only. on September 14, 2017. by guest www.bloodjournal.org From rate of oligomer formation. The observation that the number of fibers formed at 2 minutes after adding thrombin is higher for fibrinogen Philadelphia than for control ( Table 1) is consistent with a higher rate of oligomer formation. These results are very similar to the effect of antibody 7E9 on fibrin polymerization, where this antibody enhanced fibrin oligomer formation by bringing monomers together and decreased lateral aggregation by capping the ends of protofibrils so that they did not get long enough to aggregate laterally 39 . In both cases, fiber ends were observed, although this effect was more striking for 7E9 than for fibrinogen Philadelphia. Recent studies using a kinetic model for polymerization described previously 40 support the scheme presented here. In conclusion, this unique mutation may provide evidence for the importance of 378 in lateral aggregation, one of the most mysterious aspects of fibrin polymerization, although it may also affect protofibril initiation.
In other dysfibrinogenemias in which the molecular defect has been determined, the point mutations are
close to the region identified in fibrinogen Philadelphia, yet their functional properties are different.
Fibrinogen Osaka V, R375G, shows a delay in fibrin polymerization which is corrected in vitro by increasing the concentration of calcium. In this case, the defect in polymerization site "a" and calcium binding appear to be caused by the loss of the side chain of R375 41 . In fibrinogen Kaiserslautern, K380N, the additional carbohydrate content is responsible for the polymerization defect 42 . Thus, the structural and functional defect of fibrinogen Philadelphia is rather distinct.
A second abnormality associated with fibrinogen Philadelphia is the low plasma fibrinogen concentration, with a plasma level of approximately one third of normal. A unique property of this fibrinogen is the high catabolic rate compared to wild-type fibrinogen, indicative of the molecular defect being responsible for the rapid catabolism 1 . In addition, the calculated rate of synthesis was normal in one affected family member and slightly decreased in the other 1 , and the reason for the lack of compensatory synthesis is not However, since the mechanism involved in the disposal of fibrinogen is not known, we can not differentiate between the possibility that this mutation accelerates the regular mechanism of fibrinogen catabolism or that this mutation uncovers a new catabolic pathway.
The clinical expression of hypodysfibrinogenemias is similar to that of dysfibrinogenemias: bleeding, usually associated with trauma or surgical procedures, as seen in fibrinogen Philadelphia 1 , bleeding and spontaneous abortions were described in fibrinogen Bethesda III 43 , post-partum bleeding followed by thrombosis in fibrinogen Marburg 46 or post-surgical bleeding and impaired wound healing as described in fibrinogen Otago 47 .
Our biophysical and molecular analyses of fibrinogen Philadelphia polymerization suggest that lateral aggregation is sensitive to both ionic strength and calcium concentration. The structural defect of fibrinogen Philadelphia localized at the C-terminus of the chain (S378P) is unique in the described mutations of fibrinogen, and indicates that this region of the chain is functionally important in fibrin polymerization and plays a fundamental role in the formation of lateral aggregation of fibrin polymers. In addition, this substitution is likely also responsible for the high catabolic rate seen in this kindred, and further studies may uncover the pathways involved in fibrinogen catabolism. The presence of calcium ion has a profound effect on lateral aggregation, with a more pronounced difference for fibrinogen Philadelphia than for the control. In the presence of calcium, the lag period is shorter and the final turbidity is lower (Table 1 ). 
